Immuneering (IMRX) EBIAT: 2020-2023
Historic EBIAT for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$15.1 million.
- Immuneering's EBIAT fell 13.88% to -$15.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$53.5 million, marking a year-over-year decrease of 5.86%. This contributed to the annual value of -$53.5 million for FY2023, which is 5.86% down from last year.
- As of Q4 2023, Immuneering's EBIAT stood at -$15.1 million, which was down 19.76% from -$12.6 million recorded in Q3 2023.
- Immuneering's 5-year EBIAT high stood at -$3.2 million for Q2 2020, and its period low was -$15.1 million during Q4 2023.
- Over the past 3 years, Immuneering's median EBIAT value was -$12.4 million (recorded in 2023), while the average stood at -$11.5 million.
- As far as peak fluctuations go, Immuneering's EBIAT crashed by 149.56% in 2021, and later climbed by 1.94% in 2023.
- Over the past 4 years, Immuneering's EBIAT (Quarterly) stood at -$5.8 million in 2020, then crashed by 84.79% to -$10.8 million in 2021, then dropped by 22.82% to -$13.2 million in 2022, then decreased by 13.88% to -$15.1 million in 2023.
- Its EBIAT was -$15.1 million in Q4 2023, compared to -$12.6 million in Q3 2023 and -$12.2 million in Q2 2023.